Despite stringent reimbursement regulations and the ongoing safety controversy surrounding GBCAs, the European contrast agent and radiopharmaceutical market will exhibit slight growth through 2027, propelled by ASP hikes in the radiopharmaceutical space and the increasing demand for diagnostic imaging procedures for Europe's aging population. 

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in Europe across a 10-year period.


Recent studies have questioned the safety of GBCAs. 

How has the EMA responded to studies that call into question the safety of GBCAs?

To what extent will these studies impact the MRI contrast agent market through 2027?

How can competitors best respond to these safety concerns such that the impact on their products and revenues can be minimized?

Global fluctuations in the supply of Mo-99the key isotope in the production of Tc for use in most SPECT procedureswill continue to negatively impact the market going forward.

To what extent will supply limitations affect revenue growth in the European SPECT radiopharmaceutical market?

Less contrast material is being used per patient procedure in Europe.

What are some of the key factors driving this trend?

What novel technology will contribute to this trend in the future?

Which markets will be the most impacted by this shift in usage?

The European market is more competitive compared to the US market.

What are the key factors end users look for in a product?

How do local competitors fare compared to MNCs in the European contrast agent and radiopharmaceutical market?

How can smaller companies best position themselves to garner more market share going forward?

Table of contents

  • Europe
    • Abstract
    • Executive Summary
      • Market Highlights
      • Competitive Highlights
      • Market Developments
      • Geographies Covered
      • Procedures and Products Covered
    • Version History
    • Contrast Agent and Radiopharmaceutical Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Shares
      • Market Developments
      • Competitive Factors and Strategies
        • Regulatory Environment
        • Pricing Strategies and Purchasing Options
        • Mergers, Acquisitions, and Partnerships
        • Negative Press
        • Competition from Alternatives
        • Market Appeal
        • Product Improvements and Innovations
    • Radiopharmaceutical Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • SPECT Radiopharmaceuticals
        • PET Radiopharmaceuticals
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
    • CT and X-Ray Contrast Agent Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • Computed Tomography
        • Cardiovascular X-Ray
        • Conventional X-Ray
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
    • MRI Contrast Agent Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Negative Press
        • Product Improvements and Innovations
    • Ultrasound Contrast Agent Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Share Rankings
      • Competitive Factors and Strategies
    • Appendix
      • Abbreviations
      • Bibliography

Author(s): Christian Gualtieri, MSc

Christian Gualtieri is an analyst within the Hardware Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Christian holds Bachelor's and Master's degrees in Biochemistry from McGill University.


Related Reports

Contrast Agents and Radiopharmaceuticals | Medtech 360 | Market Insights | United States

Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and

View Details